Ward LM, Bardai G, Moffatt P, Al-Jallad H, Trejo P, Glorieux FH, Rauch F (2016) Osteogenesis imperfecta type VI in individuals from Northern Canada. Calcif Tissue Int 98(6):566–572. https://doi.org/10.1007/s00223-016-0110-1

Article  CAS  PubMed  Google Scholar 

Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R (2002) Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 17(1):30–38. https://doi.org/10.1359/jbmr.2002.17.1.30

Article  PubMed  Google Scholar 

Trejo P, Palomo T, Montpetit K, Fassier F, Sato A, Glorieux FH, Rauch F (2017) Long-term follow-up in osteogenesis imperfecta type VI. Osteoporos Int 28(10):2975–2983. https://doi.org/10.1007/s00198-017-4141-x

Article  CAS  PubMed  Google Scholar 

Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48(4):677–692. https://doi.org/10.1016/j.bone.2010.11.020

Article  CAS  PubMed  Google Scholar 

Trejo P, Rauch F, Ward LM (2018) Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI. J Musculoskelet Neuronal Interact 18(1):76–80

CAS  PubMed  PubMed Central  Google Scholar 

Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, Hero B, Schoenau E, Semler O (2016) Safety and efficacy of denosumab in children with osteogenesis imperfecta: a first prospective trial. J Musculoskelet Neuronal Interact 16(1):24–32

CAS  PubMed  PubMed Central  Google Scholar 

Land C, Rauch F, Travers R, Glorieux FH (2007) Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 40(3):638–644. https://doi.org/10.1016/j.bone.2006.10.010

Article  CAS  PubMed  Google Scholar 

Glorieux FH, Travers R, Taylor A, Bowen JR, Rauch F, Norman M, Parfitt AM (2000) Normative data for iliac bone histomorphometry in growing children. Bone 26(2):103–109. https://doi.org/10.1016/s8756-3282(99)00257-4

Article  CAS  PubMed  Google Scholar 

McDonald MM, Khoo WH, Ng PY, Xiao Y, Zamerli J, Thatcher P, Kyaw W, Pathmanandavel K, Grootveld AK, Moran I et al (2021) Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184(5):1330-1347.e13. https://doi.org/10.1016/j.cell.2021.02.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boyce AM (2017) Denosumab: an emerging therapy in pediatric bone disorders. Curr Osteoporos Rep 15(4):283–292. https://doi.org/10.1007/s11914-017-0380-1

Article  PubMed  PubMed Central  Google Scholar 

Anastasilakis AD, Makras P, Doulgeraki A, Polyzos SA, Guarnieri V, Papapoulos SE (2021) Denosumab for the treatment of primary pediatric osteoporosis. Osteoporos Int 32(11):2377–2381. https://doi.org/10.1007/s00198-021-06002-5

Article  CAS  PubMed  Google Scholar 

Horiuchi K, Kobayashi E, Mizuno T, Susa M, Chiba K (2021) Hypercalcemia following discontinuation of denosumab therapy: a systematic review. Bone Rep 15:101148. https://doi.org/10.1016/j.bonr.2021.101148

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sydlik C, Dürr HR, Pozza SBD, Weißenbacher C, Roeb J, Schmidt H (2020) Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention? World J Pediatr 16(5):520–527. https://doi.org/10.1007/s12519-020-00378-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brown JP, Roux C, Törring O, Ho PR, Beck Jensen JE, Gilchrist N, Recknor C, Austin M, Wang A, Grauer A, Wagman RB (2013) Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res 28(4):746–752. https://doi.org/10.1002/jbmr.1808

Article  CAS  PubMed  Google Scholar 

Vanderniet JA, Wall CL, Mullins A, London K, Lim L, Hibbert S, Briody J, Padhye B, Poon M, Biggin A, Dalla-Pozza L, Munns CF (2022) Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre. Bone 159:116395. https://doi.org/10.1016/j.bone.2022.116395

Article  CAS  PubMed  Google Scholar 

Sølling AS, Harsløf T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36(7):1245–1254. https://doi.org/10.1002/jbmr.4305

Article  CAS  PubMed  Google Scholar 

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11–17. https://doi.org/10.1016/j.bone.2017.08.003

Article  PubMed  Google Scholar 

Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A (2021) Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med 10(1):152. https://doi.org/10.3390/jcm10010152

Article  CAS  PubMed  PubMed Central  Google Scholar